ISRCTN17157458进行中（未招募）2 期
A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed-dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 386
研究概览
简要总结
2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38636725/ (added 22/04/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. HIV-1 infected children who are virologically suppressed for at least the last 6 months prior to enrolment
- •2. Aged 2 to <15 years
- •3. Weight 6 kg or higher
- •4. Children on the same triple-drug PI/r-, NNRTI- or INSTI-containing ART regimen for at least 3 months
- •5. Girls who have reached menarche must have a negative pregnancy test at screening and randomisation
- •6. Girls who are sexually active must be willing to adhere to highly effective methods of contraception
- •7. A parent or legal guardian is willing and able to give informed consent on behalf of the child as per national legislation and willing to adhere to the protocol
- •8. Participant is willing to give informed assent if the trial site clinician deems them old enough and able to understand the age-appropriate information about participation in the study
排除标准
- •1. Any previous switch in ART regimen for virological, immunological or clinical treatment failure
- •2. Any changes in ART in the last 6 months for reasons other than due to child’s growth, drug stock-outs, changes in country guidelines and treatment simplification
- •3. Evidence of previous resistance to 3TC or INSTI
- •4. Any prior use of regimens consisting of single or dual NRTIs with the exception of a course of zidovudine for prevention of mother-to-child transmission (PMTCT)
- •5. Known allergy or contraindications to dolutegravir or lamivudine
- •6. Diagnosis of tuberculosis and on anti-tuberculosis treatment; children can be enrolled after successful tuberculosis treatment
- •7. Treatment of co-morbidities with drugs which have significant interactions with antiretroviral treatment, requiring dose adjustment of the study drugs (children can be enrolled after the illness resolves)
- •8. Randomisation visit more than 12 weeks after the most recent screening visit
- •9. Evidence of hepatitis B virus (HBV) infection with no protective immunity against hepatitis B: participants positive for HBsAg or HBcAb and negative for HBsAb
- •10. Anticipated need for hepatitis C virus (HCV) therapy with interferon-based regimen prior to the primary endpoint.
- •11. Screening ALT equal to 3 or more times the upper limit of normal AND bilirubin equal to 2 or more times the upper limit of normal (ALT =3xULN AND bilirubin =2xULN)
- •12. Screening ALT equal to 5 or more times the upper limit of normal ALT (=5xULN)
- •13. Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- •14. Screening creatinine clearance <50 ml/min/1.73 m2
- •15. Patients aged =6 years at moderate or high risk of suicide as determined by Columbia-Suicide Severity Rating Scale (C-SSRS)
- •16. Girls who are pregnant or breastfeeding
- •17. Children who are in the legal custody of the state and do not have a parent or guardian able to provide informed consent on their behalf
研究者
相似试验
进行中（未招募）
不适用
Flexor injury rehabilitation splint trialInjuries and accidentsInjury, Occupational Diseases, PoisoningISRCTN10236011niversity Hospitals of Derby and Burton NHS Foundation Trust430
进行中（未招募）
4 期
Pneumococcal Vaccine Schedules (PVS)Streptococcus pneumoniae disease and pneumococcal colonisationInfections and InfestationsStreptococcus pneumoniae infectionISRCTN15056916ondon School of Hygiene & Tropical Medicine50,000
已完成
不适用
Alleviating specific phobias experienced by children trial (ASPECT)ISRCTN19883421eeds and York Partnership NHS Foundation Trust274
进行中（未招募）
不适用
Autologous stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing-remitting multiple sclerosisMultiple sclerosisRelapsing-remitting multiple sclerosisNervous System DiseasesISRCTN88667898Sheffield Teaching Hospitals NHS Foundation Trust198
进行中（未招募）
Unknown
A study regarding rest, recreation and spending time outdoors as support for health and well-being of young cancer survivorsISRCTN93856392Mid Sweden University150